Abstract
RelevanceChronic post-embolic pulmonary hypertension (CPEPH) is a complication of pulmonary thromboembolism found almost in every 10th patient. A special risk group consists of patients with a moderately high risk of pulmonary embolism associated death according to stratification of the probability of early death of the European Society of Cardiology. The development of this condition is potentially preventable with timely and adequate therapy in these patients. We have improved the approach to the treatment of pulmonary embolism patients, which allows indications for thrombolytic therapy to be clarified and expanded. The aim of the study is to evaluate its effectiveness in the long-term period, as well as analyze the qualities of life of patients with massive pulmonary embolism, who underwent thrombolytic and anticoagulant therapy.Material and methodsThe treatment, as well as the analysis of long-term results and quality of life of 71 patients aged 29 to 88 years with diagnosed pulmonary embolism with a moderately high risk of early death were performed. All patients underwent general clinical and biochemical blood tests, D-dimer, ECG, echocardiography, ultrasound of the lower extremities veins, CT angiopulmonography. We registered the dynamics of echocardiographic symptoms of the right heart overload over 6 months (right ventricle size, pulmonary hypertension, the degree of tricuspid regurgitation), and assessed the quality of life based on a survey with the establishment of the appearance of shortness of breath, tachycardia, hospitalizations for heart failure during the study period. Depending on the type of therapy, the patients were divided into two groups: 38 patients with thrombolytic therapy and 33 patients with anticoagulant therapy. Subsequently, their comparative analysis was carried out.Results and conclusionIn patients with pulmonary embolism of moderately high risk of early death, who underwent thrombolytic therapy, chronic postembolic pulmonary hypertension developed 2.9 times less and a higher quality of life retained in these patients than in patients treated with anticoagulant drugs.
Highlights
Отделение реанимации и интенсивной терапии для больных кардиологического профиля Национальный медико-хирургический центр им
Через 6 месяцев проводили контроль динамики ЭхоКГ-симптомов перегрузки правых отделов сердца, а также оценивали качество жизни на основании опроса с установлением появления одышки, тахикардии, частоты госпитализаций по поводу сердечной недостаточности за исследуемый период
Candidate of Medical Sciences, Cardiologist of Intensive Care Unit for Cardiac Patients, https://orcid.org/0000-00028530-2467
Summary
Хроническая посттромбоэмболическая легочная гипертензия (ХТЭЛГ) является осложнением тромбоэмболии легочной артерии (ТЭЛА) почти у каждого 10-го больного. Оценить его эффективность через 6 месяцев, а также проанализировать качество жизни пациентов с массивной ТЭЛА, которым была проведена тромболитическая и антикоагулянтная (АКТ) терапия, стало целью данного ретроспективного исследования. А также анализ результатов терапии и качества жизни через 6 месяцев у 71 больного в возрасте от 29 до 88 лет с диагностированной ТЭЛА умеренно-высокого риска ранней смерти. У пациентов с ТЭЛА умеренно-высокого риска ранней смерти, которым проводили ТЛТ, в 2,9 раза реже развивалась ХТЭЛГ и сохранялось более высокое качество жизни, чем у пациентов, получавших антикоагулянтные препараты. Анализ результатов лечения и качества жизни через 6 месяцев у пациентов с массивной тромбоэмболией легочной артерии на фоне лечения тромболитическими и антикоагулянтными препаратами.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Russian Sklifosovsky Journal "Emergency Medical Care"
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
